Fusion Gene Studies
in Kim Lab

FusionBase FusionGDB FusionGDB2 FusionPDB FusionNeoAntigen FusionAI FusionNW FGviewer Publication Contact
FusionGDB Logo

Home

Download

Statistics

Examples

Help

Contact
Center for Computational Systems Medicine
leaf

Fusion Gene Summary

leaf

Fusion Gene ORF analysis

leaf

Fusion Genomic Features

leaf

Fusion Protein Features

leaf

Fusion Gene Sequence

leaf

Fusion Gene PPI analysis

leaf

Related Drugs

leaf

Related Diseases

Fusion gene:EBF1-PDGFRB (FusionGDB2 ID:HG1879TG5159)

Fusion Gene Summary for EBF1-PDGFRB

check button Fusion gene summary
Fusion gene informationFusion gene name: EBF1-PDGFRB
Fusion gene ID: hg1879tg5159
HgeneTgene
Gene symbol

EBF1

PDGFRB

Gene ID

1879

5159

Gene nameEBF transcription factor 1platelet derived growth factor receptor beta
SynonymsCOE1|EBF|O/E-1|OLF1CD140B|IBGC4|IMF1|JTK12|KOGS|PDGFR|PDGFR-1|PDGFR1|PENTT
Cytomap('EBF1')('PDGFRB')

5q33.3

5q32

Type of geneprotein-codingprotein-coding
Descriptiontranscription factor COE1Collier, Olf and EBF transcription factor 1early B cell factor 1olfactory neuronal transcription factor 1platelet-derived growth factor receptor betaActivated tyrosine kinase PDGFRBCD140 antigen-like family member BNDEL1-PDGFRBPDGF-R-betaPDGFR-betabeta-type platelet-derived growth factor receptorplatelet-derived growth factor receptor 1platelet-deriv
Modification date2020032020200329
UniProtAcc.

P09619

Ensembl transtripts involved in fusion geneENST00000313708, ENST00000380654, 
ENST00000517373, ENST00000518836, 
Fusion gene scores* DoF score6 X 7 X 2=8428 X 26 X 6=4368
# samples 715
** MAII scorelog2(7/84*10)=-0.263034405833794
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0		log2(15/4368*10)=-4.86393845042397
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Context

PubMed: EBF1 [Title/Abstract] AND PDGFRB [Title/Abstract] AND fusion [Title/Abstract]

Most frequent breakpointEBF1(158134987)-PDGFRB(149506179), # samples:1
Anticipated loss of major functional domain due to fusion event.EBF1-PDGFRB seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
EBF1-PDGFRB seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
EBF1-PDGFRB seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
EBF1-PDGFRB seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgenePDGFRB

GO:0007165

signal transduction

10821867

TgenePDGFRB

GO:0010863

positive regulation of phospholipase C activity

1653029

TgenePDGFRB

GO:0018108

peptidyl-tyrosine phosphorylation

1653029|2536956|2850496

TgenePDGFRB

GO:0030335

positive regulation of cell migration

17470632

TgenePDGFRB

GO:0032516

positive regulation of phosphoprotein phosphatase activity

7691811

TgenePDGFRB

GO:0038091

positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway

17470632

TgenePDGFRB

GO:0043552

positive regulation of phosphatidylinositol 3-kinase activity

1314164

TgenePDGFRB

GO:0046777

protein autophosphorylation

1314164|2536956|2850496

TgenePDGFRB

GO:0048008

platelet-derived growth factor receptor signaling pathway

1314164|2536956

TgenePDGFRB

GO:0060326

cell chemotaxis

2554309|17991872


check buttonFusion gene breakpoints across EBF1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure
check buttonFusion gene breakpoints across PDGFRB (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check button Fusion gene information
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
SourceDiseaseSampleHgeneHchrHbpHstrandTgeneTchrTbpTstrand
ChimerKB4..EBF1chr5

158135181

-PDGFRBchr5

158135181

-


Top

Fusion Gene ORF analysis for EBF1-PDGFRB

check button Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
ORFHenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrand
intron-intronENST00000313708ENST00000261799EBF1chr5

158135181

-PDGFRBchr5

158135181

-
intron-intronENST00000313708ENST00000523456EBF1chr5

158135181

-PDGFRBchr5

158135181

-
intron-intronENST00000380654ENST00000261799EBF1chr5

158135181

-PDGFRBchr5

158135181

-
intron-intronENST00000380654ENST00000523456EBF1chr5

158135181

-PDGFRBchr5

158135181

-
intron-intronENST00000517373ENST00000261799EBF1chr5

158135181

-PDGFRBchr5

158135181

-
intron-intronENST00000517373ENST00000523456EBF1chr5

158135181

-PDGFRBchr5

158135181

-
intron-intronENST00000518836ENST00000261799EBF1chr5

158135181

-PDGFRBchr5

158135181

-
intron-intronENST00000518836ENST00000523456EBF1chr5

158135181

-PDGFRBchr5

158135181

-

check buttonORFfinder result based on the fusion transcript sequence of in-frame fusion genes.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)		BP loci
(transcript)		Predicted start
(transcript)		Predicted stop
(transcript)		Seq length
(amino acids)

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000313708ENST00000261799EBF1chr5158134987-PDGFRBchr5149506179-0.0019101310.99808985
ENST00000380654ENST00000261799EBF1chr5158134987-PDGFRBchr5149506179-0.0025884370.99741155
ENST00000517373ENST00000261799EBF1chr5158134987-PDGFRBchr5149506179-0.001121650.9988783

Top

Fusion Genomic Features for EBF1-PDGFRB


check buttonFusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints.
HgeneHchrHbpHstrandTgeneTchrTbpTstrand1-pp (fusion gene breakpoint)

check buttonDistribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page.
genomic feature

Top

Fusion Protein Features for EBF1-PDGFRB


check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr5:158134987/chr5:149506179)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonMain function of each fusion partner protein. (from UniProt)
HgeneTgene
.PDGFRB

P09619

FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}.FUNCTION: Tyrosine-protein kinase that acts as cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration. Plays an essential role in blood vessel development by promoting proliferation, migration and recruitment of pericytes and smooth muscle cells to endothelial cells. Plays a role in the migration of vascular smooth muscle cells and the formation of neointima at vascular injury sites. Required for normal development of the cardiovascular system. Required for normal recruitment of pericytes (mesangial cells) in the kidney glomerulus, and for normal formation of a branched network of capillaries in kidney glomeruli. Promotes rearrangement of the actin cytoskeleton and the formation of membrane ruffles. Binding of its cognate ligands - homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFD -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PLCG1, PIK3R1, PTPN11, RASA1/GAP, CBL, SHC1 and NCK1. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leads to the activation of the AKT1 signaling pathway. Phosphorylation of SHC1, or of the C-terminus of PTPN11, creates a binding site for GRB2, resulting in the activation of HRAS, RAF1 and down-stream MAP kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation and activation of SRC family kinases. Promotes phosphorylation of PDCD6IP/ALIX and STAM. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor. {ECO:0000269|PubMed:11297552, ECO:0000269|PubMed:11331881, ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1396585, ECO:0000269|PubMed:1653029, ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:1846866, ECO:0000269|PubMed:20494825, ECO:0000269|PubMed:20529858, ECO:0000269|PubMed:21098708, ECO:0000269|PubMed:21679854, ECO:0000269|PubMed:21733313, ECO:0000269|PubMed:2554309, ECO:0000269|PubMed:26599395, ECO:0000269|PubMed:2835772, ECO:0000269|PubMed:2850496, ECO:0000269|PubMed:7685273, ECO:0000269|PubMed:7691811, ECO:0000269|PubMed:7692233, ECO:0000269|PubMed:8195171}.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at

download page


* Minus value of BPloci means that the break pointn is located before the CDS.
- In-frame and retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
HgeneEBF1chr5:158134987chr5:149506179ENST00000313708-1516462_550581592.0Compositional biasNote=Pro/Ser/Thr-rich
HgeneEBF1chr5:158134987chr5:149506179ENST00000380654-1415462_550550561.0Compositional biasNote=Pro/Ser/Thr-rich
HgeneEBF1chr5:158134987chr5:149506179ENST00000313708-1516262_345581592.0DomainNote=IPT/TIG
HgeneEBF1chr5:158134987chr5:149506179ENST00000380654-1415262_345550561.0DomainNote=IPT/TIG
HgeneEBF1chr5:158134987chr5:149506179ENST00000313708-1516151_170581592.0Zinc fingerC5-type
HgeneEBF1chr5:158134987chr5:149506179ENST00000380654-1415151_170550561.0Zinc fingerC5-type
TgenePDGFRBchr5:158134987chr5:149506179ENST00000261799923600_9625261107.0DomainProtein kinase
TgenePDGFRBchr5:158134987chr5:149506179ENST00000261799923606_6145261107.0Nucleotide bindingATP
TgenePDGFRBchr5:158134987chr5:149506179ENST00000261799923554_11065261107.0Topological domainCytoplasmic
TgenePDGFRBchr5:158134987chr5:149506179ENST00000261799923533_5535261107.0TransmembraneHelical

- In-frame and not-retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
TgenePDGFRBchr5:158134987chr5:149506179ENST00000261799923129_2105261107.0DomainNote=Ig-like C2-type 2
TgenePDGFRBchr5:158134987chr5:149506179ENST00000261799923214_3095261107.0DomainNote=Ig-like C2-type 3
TgenePDGFRBchr5:158134987chr5:149506179ENST00000261799923331_4035261107.0DomainNote=Ig-like C2-type 4
TgenePDGFRBchr5:158134987chr5:149506179ENST0000026179992333_1205261107.0DomainNote=Ig-like C2-type 1
TgenePDGFRBchr5:158134987chr5:149506179ENST00000261799923416_5245261107.0DomainNote=Ig-like C2-type 5
TgenePDGFRBchr5:158134987chr5:149506179ENST0000026179992333_5325261107.0Topological domainExtracellular


Top

Fusion Gene Sequence for EBF1-PDGFRB


check button For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones.
>24821_24821_1_EBF1-PDGFRB_EBF1_chr5_158134987_ENST00000313708_PDGFRB_chr5_149506179_ENST00000261799_length(transcript)=5695nt_BP=2027nt
GCCAAGCATACATCTCTAATTTTATTATTTTGGTCTTTTCGTTGGATTTTCCCTTTCTTCTTTTTTTCGGGTTATCGCTCAGTTTTGAGC
AGAGGTTTACATTTTTTAAAAATTTGCTTTCCAGCCCGCCTTGATCTTCTAAGTGCGAGTTCATCGTCTGAGAAAAAAAAAAATCTCTGG
TTGGCGTTTTTGTTTCTTTTCTTTTCTTTCTTTTCTTTCCTTTTTTTTTTTTTTTAATTTTTTTCAAGGGGGAGGAGATTTTCCACAAGA
AAAGGTTGTTTTCATGTTTGGGATTCAGGAAAGCATCCAACGGAGTGGAAGCAGCATGAAGGAAGAGCCGCTGGGCAGCGGCATGAACGC
GGTGCGGACGTGGATGCAGGGCGCCGGGGTGCTGGACGCCAACACGGCGGCGCAGAGCGGGGTGGGTCTGGCCCGGGCTCACTTTGAGAA
GCAGCCGCCTTCCAATCTGCGGAAATCCAACTTCTTCCACTTCGTCCTGGCCCTCTACGACAGACAGGGCCAGCCCGTGGAGATCGAGAG
GACAGCGTTTGTGGGGTTCGTGGAGAAGGAAAAAGAAGCCAACAGCGAAAAGACCAATAACGGAATTCACTACCGGCTTCAGCTTCTCTA
CAGCAATGGGATAAGGACGGAGCAGGATTTCTACGTGCGCCTCATTGACTCCATGACAAAACAAGCCATAGTGTATGAAGGCCAAGACAA
GAACCCAGAAATGTGCCGAGTCTTGCTCACACATGAGATCATGTGCAGCCGCTGTTGTGACAAGAAAAGCTGTGGCAACCGAAATGAGAC
TCCCTCAGATCCAGTGATAATTGACAGGTTCTTCTTGAAATTTTTCCTCAAATGTAACCAAAATTGCCTAAAGAATGCGGGAAACCCACG
TGACATGCGGAGATTCCAGGTCGTGGTGTCTACGACAGTCAATGTGGATGGCCATGTCCTGGCAGTCTCTGATAACATGTTTGTCCATAA
TAATTCCAAGCATGGGCGGAGGGCTCGGAGGCTTGACCCCTCGGAAGGTACGCCCTCTTATCTGGAACATGCTACTCCCTGTATCAAAGC
CATCAGCCCGAGTGAAGGATGGACGACGGGAGGTGCGACTGTGATCATCATAGGGGACAATTTCTTTGATGGGTTACAGGTCATATTCGG
TACCATGCTGGTCTGGAGTGAGTTGATCACTCCTCATGCCATCCGTGTGCAGACCCCTCCTCGGCACATCCCTGGTGTTGTGGAAGTCAC
ACTGTCCTACAAATCTAAGCAGTTCTGCAAAGGAACACCAGGCAGATTCATTTATACAGCGCTCAACGAACCCACCATCGATTATGGTTT
CCAGAGGTTACAGAAGGTCATTCCTCGGCACCCTGGTGACCCTGAGCGTTTGCCAAAGGAAGTAATACTCAAAAGGGCTGCGGATCTGGT
AGAAGCACTGTATGGGATGCCACACAACAACCAGGAAATCATTCTGAAGAGAGCGGCCGACATTGCCGAGGCCCTGTACAGTGTTCCCCG
CAACCACAACCAACTCCCGGCCCTTGCTAACACCTCGGTCCACGCAGGGATGATGGGCGTGAATTCGTTCAGTGGACAACTGGCCGTGAA
TGTCTCCGAGGCATCACAAGCCACCAATCAGGGTTTCACCCGCAACTCAAGCAGCGTATCACCACACGGGTACGTGCCGAGCACCACTCC
CCAGCAGACCAACTATAACTCCGTCACCACGAGCATGAACGGATACGGCTCTGCCGCAATGTCCAATTTGGGCGGCTCCCCCACCTTCCT
CAACGGCTCAGCTGCCAACTCCCCCTATGCCATAGTGCCATCCAGCCCCACCATGGCCTCCTCCACAAGCCTCCCCTCCAACTGCAGCAG
CTCCTCGGGCATCTTCTCCTTCTCACCAGCCAACATGGTCTCAGCCGTGAAACAGAAGAGTGCTTTCGCACCAGTCGTCAGACCCCAGAC
CTCCCCACCTCCCACCTGCACCAGCACCAACGGGAACAGCCTGCAAGCCTTGCCCTTTAAGGTGGTGGTGATCTCAGCCATCCTGGCCCT
GGTGGTGCTCACCATCATCTCCCTTATCATCCTCATCATGCTTTGGCAGAAGAAGCCACGTTACGAGATCCGATGGAAGGTGATTGAGTC
TGTGAGCTCTGACGGCCATGAGTACATCTACGTGGACCCCATGCAGCTGCCCTATGACTCCACGTGGGAGCTGCCGCGGGACCAGCTTGT
GCTGGGACGCACCCTCGGCTCTGGGGCCTTTGGGCAGGTGGTGGAGGCCACGGCTCATGGCCTGAGCCATTCTCAGGCCACGATGAAAGT
GGCCGTCAAGATGCTTAAATCCACAGCCCGCAGCAGTGAGAAGCAAGCCCTTATGTCGGAGCTGAAGATCATGAGTCACCTTGGGCCCCA
CCTGAACGTGGTCAACCTGTTGGGGGCCTGCACCAAAGGAGGACCCATCTATATCATCACTGAGTACTGCCGCTACGGAGACCTGGTGGA
CTACCTGCACCGCAACAAACACACCTTCCTGCAGCACCACTCCGACAAGCGCCGCCCGCCCAGCGCGGAGCTCTACAGCAATGCTCTGCC
CGTTGGGCTCCCCCTGCCCAGCCATGTGTCCTTGACCGGGGAGAGCGACGGTGGCTACATGGACATGAGCAAGGACGAGTCGGTGGACTA
TGTGCCCATGCTGGACATGAAAGGAGACGTCAAATATGCAGACATCGAGTCCTCCAACTACATGGCCCCTTACGATAACTACGTTCCCTC
TGCCCCTGAGAGGACCTGCCGAGCAACTTTGATCAACGAGTCTCCAGTGCTAAGCTACATGGACCTCGTGGGCTTCAGCTACCAGGTGGC
CAATGGCATGGAGTTTCTGGCCTCCAAGAACTGCGTCCACAGAGACCTGGCGGCTAGGAACGTGCTCATCTGTGAAGGCAAGCTGGTCAA
GATCTGTGACTTTGGCCTGGCTCGAGACATCATGCGGGACTCGAATTACATCTCCAAAGGCAGCACCTTTTTGCCTTTAAAGTGGATGGC
TCCGGAGAGCATCTTCAACAGCCTCTACACCACCCTGAGCGACGTGTGGTCCTTCGGGATCCTGCTCTGGGAGATCTTCACCTTGGGTGG
CACCCCTTACCCAGAGCTGCCCATGAACGAGCAGTTCTACAATGCCATCAAACGGGGTTACCGCATGGCCCAGCCTGCCCATGCCTCCGA
CGAGATCTATGAGATCATGCAGAAGTGCTGGGAAGAGAAGTTTGAGATTCGGCCCCCCTTCTCCCAGCTGGTGCTGCTTCTCGAGAGACT
GTTGGGCGAAGGTTACAAAAAGAAGTACCAGCAGGTGGATGAGGAGTTTCTGAGGAGTGACCACCCAGCCATCCTTCGGTCCCAGGCCCG
CTTGCCTGGGTTCCATGGCCTCCGATCTCCCCTGGACACCAGCTCCGTCCTCTATACTGCCGTGCAGCCCAATGAGGGTGACAACGACTA
TATCATCCCCCTGCCTGACCCCAAACCCGAGGTTGCTGACGAGGGCCCACTGGAGGGTTCCCCCAGCCTAGCCAGCTCCACCCTGAATGA
AGTCAACACCTCCTCAACCATCTCCTGTGACAGCCCCCTGGAGCCCCAGGACGAACCAGAGCCAGAGCCCCAGCTTGAGCTCCAGGTGGA
GCCGGAGCCAGAGCTGGAACAGTTGCCGGATTCGGGGTGCCCTGCGCCTCGGGCGGAAGCAGAGGATAGCTTCCTGTAGGGGGCTGGCCC
CTACCCTGCCCTGCCTGAAGCTCCCCCCCTGCCAGCACCCAGCATCTCCTGGCCTGGCCTGACCGGGCTTCCTGTCAGCCAGGCTGCCCT
TATCAGCTGTCCCCTTCTGGAAGCTTTCTGCTCCTGACGTGTTGTGCCCCAAACCCTGGGGCTGGCTTAGGAGGCAAGAAAACTGCAGGG
GCCGTGACCAGCCCTCTGCCTCCAGGGAGGCCAACTGACTCTGAGCCAGGGTTCCCCCAGGGAACTCAGTTTTCCCATATGTAAAATGGG
AAAGTTAGGCTTGATGACCCAGAATCTAGGATTCTCTCCCTGGCTGACAGGTGGGGAGACCGAATCCCTCCCTGGGAAGATTCTTGGAGT
TACTGAGGTGGTAAATTAACTTTTTTCTGTTCAGCCAGCTACCCCTCAAGGAATCATAGCTCTCTCCTCGCACTTTTATCCACCCAGGAG
CTAGGGAAGAGACCCTAGCCTCCCTGGCTGCTGGCTGAGCTAGGGCCTAGCCTTGAGCAGTGTTGCCTCATCCAGAAGAAAGCCAGTCTC
CTCCCTATGATGCCAGTCCCTGCGTTCCCTGGCCCGAGCTGGTCTGGGGCCATTAGGCAGCCTAATTAATGCTGGAGGCTGAGCCAAGTA
CAGGACACCCCCAGCCTGCAGCCCTTGCCCAGGGCACTTGGAGCACACGCAGCCATAGCAAGTGCCTGTGTCCCTGTCCTTCAGGCCCAT
CAGTCCTGGGGCTTTTTCTTTATCACCCTCAGTCTTAATCCATCCACCAGAGTCTAGAAGGCCAGACGGGCCCCGCATCTGTGATGAGAA
TGTAAATGTGCCAGTGTGGAGTGGCCACGTGTGTGTGCCAGTATATGGCCCTGGCTCTGCATTGGACCTGCTATGAGGCTTTGGAGGAAT
CCCTCACCCTCTCTGGGCCTCAGTTTCCCCTTCAAAAAATGAATAAGTCGGACTTATTAACTCTGAGTGCCTTGCCAGCACTAACATTCT
AGAGTATTCCAGGTGGTTGCACATTTGTCCAGATGAAGCAAGGCCATATACCCTAAACTTCCATCCTGGGGGTCAGCTGGGCTCCTGGGA
GATTCCAGATCACACATCACACTCTGGGGACTCAGGAACCATGCCCCTTCCCCAGGCCCCCAGCAAGTCTCAAGAACACAGCTGCACAGG
CCTTGACTTAGAGTGACAGCCGGTGTCCTGGAAAGCCCCCAGCAGCTGCCCCAGGGACATGGGAAGACCACGGGACCTCTTTCACTACCC
ACGATGACCTCCGGGGGTATCCTGGGCAAAAGGGACAAAGAGGGCAAATGAGATCACCTCCTGCAGCCCACCACTCCAGCACCTGTGCCG
AGGTCTGCGTCGAAGACAGAATGGACAGTGAGGACAGTTATGTCTTGTAAAAGACAAGAAGCTTCAGATGGGTACCCCAAGAAGGATGTG
AGAGGTGGGCGCTTTGGAGGTTTGCCCCTCACCCACCAGCTGCCCCATCCCTGAGGCAGCGCTCCATGGGGGTATGGTTTTGTCACTGCC
CAGACCTAGCAGTGACATCTCATTGTCCCCAGCCCAGTGGGCATTGGAGGTGCCAGGGGAGTCAGGGTTGTAGCCAAGACGCCCCCGCAC
GGGGAGGGTTGGGAAGGGGGTGCAGGAAGCTCAACCCCTCTGGGCACCAACCCTGCATTGCAGGTTGGCACCTTACTTCCCTGGGATCCC
CAGAGTTGGTCCAAGGAGGGAGAGTGGGTTCTCAATACGGTACCAAAGATATAATCACCTAGGTTTACAAATATTTTTAGGACTCACGTT
AACTCACATTTATACAGCAGAAATGCTATTTTGTATGCTGTTGAGTTTTTCTATCTGTGTACTTTTTTTTAAGGGAAAGATTTTAATATT
AAACCTGGTGCTTCTCACTCACAGA

>24821_24821_1_EBF1-PDGFRB_EBF1_chr5_158134987_ENST00000313708_PDGFRB_chr5_149506179_ENST00000261799_length(amino acids)=1203AA_BP=623
MRKKKISGWRFCFFSFLSFLSFFFFFNFFQGGGDFPQEKVVFMFGIQESIQRSGSSMKEEPLGSGMNAVRTWMQGAGVLDANTAAQSGVG
LARAHFEKQPPSNLRKSNFFHFVLALYDRQGQPVEIERTAFVGFVEKEKEANSEKTNNGIHYRLQLLYSNGIRTEQDFYVRLIDSMTKQA
IVYEGQDKNPEMCRVLLTHEIMCSRCCDKKSCGNRNETPSDPVIIDRFFLKFFLKCNQNCLKNAGNPRDMRRFQVVVSTTVNVDGHVLAV
SDNMFVHNNSKHGRRARRLDPSEGTPSYLEHATPCIKAISPSEGWTTGGATVIIIGDNFFDGLQVIFGTMLVWSELITPHAIRVQTPPRH
IPGVVEVTLSYKSKQFCKGTPGRFIYTALNEPTIDYGFQRLQKVIPRHPGDPERLPKEVILKRAADLVEALYGMPHNNQEIILKRAADIA
EALYSVPRNHNQLPALANTSVHAGMMGVNSFSGQLAVNVSEASQATNQGFTRNSSSVSPHGYVPSTTPQQTNYNSVTTSMNGYGSAAMSN
LGGSPTFLNGSAANSPYAIVPSSPTMASSTSLPSNCSSSSGIFSFSPANMVSAVKQKSAFAPVVRPQTSPPPTCTSTNGNSLQALPFKVV
VISAILALVVLTIISLIILIMLWQKKPRYEIRWKVIESVSSDGHEYIYVDPMQLPYDSTWELPRDQLVLGRTLGSGAFGQVVEATAHGLS
HSQATMKVAVKMLKSTARSSEKQALMSELKIMSHLGPHLNVVNLLGACTKGGPIYIITEYCRYGDLVDYLHRNKHTFLQHHSDKRRPPSA
ELYSNALPVGLPLPSHVSLTGESDGGYMDMSKDESVDYVPMLDMKGDVKYADIESSNYMAPYDNYVPSAPERTCRATLINESPVLSYMDL
VGFSYQVANGMEFLASKNCVHRDLAARNVLICEGKLVKICDFGLARDIMRDSNYISKGSTFLPLKWMAPESIFNSLYTTLSDVWSFGILL
WEIFTLGGTPYPELPMNEQFYNAIKRGYRMAQPAHASDEIYEIMQKCWEEKFEIRPPFSQLVLLLERLLGEGYKKKYQQVDEEFLRSDHP
AILRSQARLPGFHGLRSPLDTSSVLYTAVQPNEGDNDYIIPLPDPKPEVADEGPLEGSPSLASSTLNEVNTSSTISCDSPLEPQDEPEPE
PQLELQVEPEPELEQLPDSGCPAPRAEAEDSFL

--------------------------------------------------------------
>24821_24821_2_EBF1-PDGFRB_EBF1_chr5_158134987_ENST00000380654_PDGFRB_chr5_149506179_ENST00000261799_length(transcript)=5534nt_BP=1866nt
GGGTTATCGCTCAGTTTTGAGCAGAGGTTTACATTTTTTAAAAATTTGCTTTCCAGCCCGCCTTGATCTTCTAAGTGCGAGTTCATCGTC
TGAGAAAAAAAAAAATCTCTGGTTGGCGTTTTTGTTTCTTTTCTTTTCTTTCTTTTCTTTCCTTTTTTTTTTTTTTTAATTTTTTTCAAG
GGGGAGGAGATTTTCCACAAGAAAAGGTTGTTTTCATGTTTGGGATTCAGGAAAGCATCCAACGGAGTGGAAGCAGCATGAAGGAAGAGC
CGCTGGGCAGCGGCATGAACGCGGTGCGGACGTGGATGCAGGGCGCCGGGGTGCTGGACGCCAACACGGCGGCGCAGAGCGGGGTGGGTC
TGGCCCGGGCTCACTTTGAGAAGCAGCCGCCTTCCAATCTGCGGAAATCCAACTTCTTCCACTTCGTCCTGGCCCTCTACGACAGACAGG
GCCAGCCCGTGGAGATCGAGAGGACAGCGTTTGTGGGGTTCGTGGAGAAGGAAAAAGAAGCCAACAGCGAAAAGACCAATAACGGAATTC
ACTACCGGCTTCAGCTTCTCTACAGCAATGGGATAAGGACGGAGCAGGATTTCTACGTGCGCCTCATTGACTCCATGACAAAACAAGCCA
TAGTGTATGAAGGCCAAGACAAGAACCCAGAAATGTGCCGAGTCTTGCTCACACATGAGATCATGTGCAGGTTCTTCTTGAAATTTTTCC
TCAAATGTAACCAAAATTGCCTAAAGAATGCGGGAAACCCACGTGACATGCGGAGATTCCAGGTCGTGGTGTCTACGACAGTCAATGTGG
ATGGCCATGTCCTGGCAGTCTCTGATAACATGTTTGTCCATAATAATTCCAAGCATGGGCGGAGGGCTCGGAGGCTTGACCCCTCGGAAG
CTACTCCCTGTATCAAAGCCATCAGCCCGAGTGAAGGATGGACGACGGGAGGTGCGACTGTGATCATCATAGGGGACAATTTCTTTGATG
GGTTACAGGTCATATTCGGTACCATGCTGGTCTGGAGTGAGTTGATCACTCCTCATGCCATCCGTGTGCAGACCCCTCCTCGGCACATCC
CTGGTGTTGTGGAAGTCACACTGTCCTACAAATCTAAGCAGTTCTGCAAAGGAACACCAGGCAGATTCATTTATACAGCGCTCAACGAAC
CCACCATCGATTATGGTTTCCAGAGGTTACAGAAGGTCATTCCTCGGCACCCTGGTGACCCTGAGCGTTTGCCAAAGGAAGTAATACTCA
AAAGGGCTGCGGATCTGGTAGAAGCACTGTATGGGATGCCACACAACAACCAGGAAATCATTCTGAAGAGAGCGGCCGACATTGCCGAGG
CCCTGTACAGTGTTCCCCGCAACCACAACCAACTCCCGGCCCTTGCTAACACCTCGGTCCACGCAGGGATGATGGGCGTGAATTCGTTCA
GTGGACAACTGGCCGTGAATGTCTCCGAGGCATCACAAGCCACCAATCAGGGTTTCACCCGCAACTCAAGCAGCGTATCACCACACGGGT
ACGTGCCGAGCACCACTCCCCAGCAGACCAACTATAACTCCGTCACCACGAGCATGAACGGATACGGCTCTGCCGCAATGTCCAATTTGG
GCGGCTCCCCCACCTTCCTCAACGGCTCAGCTGCCAACTCCCCCTATGCCATAGTGCCATCCAGCCCCACCATGGCCTCCTCCACAAGCC
TCCCCTCCAACTGCAGCAGCTCCTCGGGCATCTTCTCCTTCTCACCAGCCAACATGGTCTCAGCCGTGAAACAGAAGAGTGCTTTCGCAC
CAGTCGTCAGACCCCAGACCTCCCCACCTCCCACCTGCACCAGCACCAACGGGAACAGCCTGCAAGCCTTGCCCTTTAAGGTGGTGGTGA
TCTCAGCCATCCTGGCCCTGGTGGTGCTCACCATCATCTCCCTTATCATCCTCATCATGCTTTGGCAGAAGAAGCCACGTTACGAGATCC
GATGGAAGGTGATTGAGTCTGTGAGCTCTGACGGCCATGAGTACATCTACGTGGACCCCATGCAGCTGCCCTATGACTCCACGTGGGAGC
TGCCGCGGGACCAGCTTGTGCTGGGACGCACCCTCGGCTCTGGGGCCTTTGGGCAGGTGGTGGAGGCCACGGCTCATGGCCTGAGCCATT
CTCAGGCCACGATGAAAGTGGCCGTCAAGATGCTTAAATCCACAGCCCGCAGCAGTGAGAAGCAAGCCCTTATGTCGGAGCTGAAGATCA
TGAGTCACCTTGGGCCCCACCTGAACGTGGTCAACCTGTTGGGGGCCTGCACCAAAGGAGGACCCATCTATATCATCACTGAGTACTGCC
GCTACGGAGACCTGGTGGACTACCTGCACCGCAACAAACACACCTTCCTGCAGCACCACTCCGACAAGCGCCGCCCGCCCAGCGCGGAGC
TCTACAGCAATGCTCTGCCCGTTGGGCTCCCCCTGCCCAGCCATGTGTCCTTGACCGGGGAGAGCGACGGTGGCTACATGGACATGAGCA
AGGACGAGTCGGTGGACTATGTGCCCATGCTGGACATGAAAGGAGACGTCAAATATGCAGACATCGAGTCCTCCAACTACATGGCCCCTT
ACGATAACTACGTTCCCTCTGCCCCTGAGAGGACCTGCCGAGCAACTTTGATCAACGAGTCTCCAGTGCTAAGCTACATGGACCTCGTGG
GCTTCAGCTACCAGGTGGCCAATGGCATGGAGTTTCTGGCCTCCAAGAACTGCGTCCACAGAGACCTGGCGGCTAGGAACGTGCTCATCT
GTGAAGGCAAGCTGGTCAAGATCTGTGACTTTGGCCTGGCTCGAGACATCATGCGGGACTCGAATTACATCTCCAAAGGCAGCACCTTTT
TGCCTTTAAAGTGGATGGCTCCGGAGAGCATCTTCAACAGCCTCTACACCACCCTGAGCGACGTGTGGTCCTTCGGGATCCTGCTCTGGG
AGATCTTCACCTTGGGTGGCACCCCTTACCCAGAGCTGCCCATGAACGAGCAGTTCTACAATGCCATCAAACGGGGTTACCGCATGGCCC
AGCCTGCCCATGCCTCCGACGAGATCTATGAGATCATGCAGAAGTGCTGGGAAGAGAAGTTTGAGATTCGGCCCCCCTTCTCCCAGCTGG
TGCTGCTTCTCGAGAGACTGTTGGGCGAAGGTTACAAAAAGAAGTACCAGCAGGTGGATGAGGAGTTTCTGAGGAGTGACCACCCAGCCA
TCCTTCGGTCCCAGGCCCGCTTGCCTGGGTTCCATGGCCTCCGATCTCCCCTGGACACCAGCTCCGTCCTCTATACTGCCGTGCAGCCCA
ATGAGGGTGACAACGACTATATCATCCCCCTGCCTGACCCCAAACCCGAGGTTGCTGACGAGGGCCCACTGGAGGGTTCCCCCAGCCTAG
CCAGCTCCACCCTGAATGAAGTCAACACCTCCTCAACCATCTCCTGTGACAGCCCCCTGGAGCCCCAGGACGAACCAGAGCCAGAGCCCC
AGCTTGAGCTCCAGGTGGAGCCGGAGCCAGAGCTGGAACAGTTGCCGGATTCGGGGTGCCCTGCGCCTCGGGCGGAAGCAGAGGATAGCT
TCCTGTAGGGGGCTGGCCCCTACCCTGCCCTGCCTGAAGCTCCCCCCCTGCCAGCACCCAGCATCTCCTGGCCTGGCCTGACCGGGCTTC
CTGTCAGCCAGGCTGCCCTTATCAGCTGTCCCCTTCTGGAAGCTTTCTGCTCCTGACGTGTTGTGCCCCAAACCCTGGGGCTGGCTTAGG
AGGCAAGAAAACTGCAGGGGCCGTGACCAGCCCTCTGCCTCCAGGGAGGCCAACTGACTCTGAGCCAGGGTTCCCCCAGGGAACTCAGTT
TTCCCATATGTAAAATGGGAAAGTTAGGCTTGATGACCCAGAATCTAGGATTCTCTCCCTGGCTGACAGGTGGGGAGACCGAATCCCTCC
CTGGGAAGATTCTTGGAGTTACTGAGGTGGTAAATTAACTTTTTTCTGTTCAGCCAGCTACCCCTCAAGGAATCATAGCTCTCTCCTCGC
ACTTTTATCCACCCAGGAGCTAGGGAAGAGACCCTAGCCTCCCTGGCTGCTGGCTGAGCTAGGGCCTAGCCTTGAGCAGTGTTGCCTCAT
CCAGAAGAAAGCCAGTCTCCTCCCTATGATGCCAGTCCCTGCGTTCCCTGGCCCGAGCTGGTCTGGGGCCATTAGGCAGCCTAATTAATG
CTGGAGGCTGAGCCAAGTACAGGACACCCCCAGCCTGCAGCCCTTGCCCAGGGCACTTGGAGCACACGCAGCCATAGCAAGTGCCTGTGT
CCCTGTCCTTCAGGCCCATCAGTCCTGGGGCTTTTTCTTTATCACCCTCAGTCTTAATCCATCCACCAGAGTCTAGAAGGCCAGACGGGC
CCCGCATCTGTGATGAGAATGTAAATGTGCCAGTGTGGAGTGGCCACGTGTGTGTGCCAGTATATGGCCCTGGCTCTGCATTGGACCTGC
TATGAGGCTTTGGAGGAATCCCTCACCCTCTCTGGGCCTCAGTTTCCCCTTCAAAAAATGAATAAGTCGGACTTATTAACTCTGAGTGCC
TTGCCAGCACTAACATTCTAGAGTATTCCAGGTGGTTGCACATTTGTCCAGATGAAGCAAGGCCATATACCCTAAACTTCCATCCTGGGG
GTCAGCTGGGCTCCTGGGAGATTCCAGATCACACATCACACTCTGGGGACTCAGGAACCATGCCCCTTCCCCAGGCCCCCAGCAAGTCTC
AAGAACACAGCTGCACAGGCCTTGACTTAGAGTGACAGCCGGTGTCCTGGAAAGCCCCCAGCAGCTGCCCCAGGGACATGGGAAGACCAC
GGGACCTCTTTCACTACCCACGATGACCTCCGGGGGTATCCTGGGCAAAAGGGACAAAGAGGGCAAATGAGATCACCTCCTGCAGCCCAC
CACTCCAGCACCTGTGCCGAGGTCTGCGTCGAAGACAGAATGGACAGTGAGGACAGTTATGTCTTGTAAAAGACAAGAAGCTTCAGATGG
GTACCCCAAGAAGGATGTGAGAGGTGGGCGCTTTGGAGGTTTGCCCCTCACCCACCAGCTGCCCCATCCCTGAGGCAGCGCTCCATGGGG
GTATGGTTTTGTCACTGCCCAGACCTAGCAGTGACATCTCATTGTCCCCAGCCCAGTGGGCATTGGAGGTGCCAGGGGAGTCAGGGTTGT
AGCCAAGACGCCCCCGCACGGGGAGGGTTGGGAAGGGGGTGCAGGAAGCTCAACCCCTCTGGGCACCAACCCTGCATTGCAGGTTGGCAC
CTTACTTCCCTGGGATCCCCAGAGTTGGTCCAAGGAGGGAGAGTGGGTTCTCAATACGGTACCAAAGATATAATCACCTAGGTTTACAAA
TATTTTTAGGACTCACGTTAACTCACATTTATACAGCAGAAATGCTATTTTGTATGCTGTTGAGTTTTTCTATCTGTGTACTTTTTTTTA
AGGGAAAGATTTTAATATTAAACCTGGTGCTTCTCACTCACAGA

>24821_24821_2_EBF1-PDGFRB_EBF1_chr5_158134987_ENST00000380654_PDGFRB_chr5_149506179_ENST00000261799_length(amino acids)=1172AA_BP=592
MRKKKISGWRFCFFSFLSFLSFFFFFNFFQGGGDFPQEKVVFMFGIQESIQRSGSSMKEEPLGSGMNAVRTWMQGAGVLDANTAAQSGVG
LARAHFEKQPPSNLRKSNFFHFVLALYDRQGQPVEIERTAFVGFVEKEKEANSEKTNNGIHYRLQLLYSNGIRTEQDFYVRLIDSMTKQA
IVYEGQDKNPEMCRVLLTHEIMCRFFLKFFLKCNQNCLKNAGNPRDMRRFQVVVSTTVNVDGHVLAVSDNMFVHNNSKHGRRARRLDPSE
ATPCIKAISPSEGWTTGGATVIIIGDNFFDGLQVIFGTMLVWSELITPHAIRVQTPPRHIPGVVEVTLSYKSKQFCKGTPGRFIYTALNE
PTIDYGFQRLQKVIPRHPGDPERLPKEVILKRAADLVEALYGMPHNNQEIILKRAADIAEALYSVPRNHNQLPALANTSVHAGMMGVNSF
SGQLAVNVSEASQATNQGFTRNSSSVSPHGYVPSTTPQQTNYNSVTTSMNGYGSAAMSNLGGSPTFLNGSAANSPYAIVPSSPTMASSTS
LPSNCSSSSGIFSFSPANMVSAVKQKSAFAPVVRPQTSPPPTCTSTNGNSLQALPFKVVVISAILALVVLTIISLIILIMLWQKKPRYEI
RWKVIESVSSDGHEYIYVDPMQLPYDSTWELPRDQLVLGRTLGSGAFGQVVEATAHGLSHSQATMKVAVKMLKSTARSSEKQALMSELKI
MSHLGPHLNVVNLLGACTKGGPIYIITEYCRYGDLVDYLHRNKHTFLQHHSDKRRPPSAELYSNALPVGLPLPSHVSLTGESDGGYMDMS
KDESVDYVPMLDMKGDVKYADIESSNYMAPYDNYVPSAPERTCRATLINESPVLSYMDLVGFSYQVANGMEFLASKNCVHRDLAARNVLI
CEGKLVKICDFGLARDIMRDSNYISKGSTFLPLKWMAPESIFNSLYTTLSDVWSFGILLWEIFTLGGTPYPELPMNEQFYNAIKRGYRMA
QPAHASDEIYEIMQKCWEEKFEIRPPFSQLVLLLERLLGEGYKKKYQQVDEEFLRSDHPAILRSQARLPGFHGLRSPLDTSSVLYTAVQP
NEGDNDYIIPLPDPKPEVADEGPLEGSPSLASSTLNEVNTSSTISCDSPLEPQDEPEPEPQLELQVEPEPELEQLPDSGCPAPRAEAEDS
FL

--------------------------------------------------------------
>24821_24821_3_EBF1-PDGFRB_EBF1_chr5_158134987_ENST00000517373_PDGFRB_chr5_149506179_ENST00000261799_length(transcript)=5491nt_BP=1823nt
GCCAAGCATACATCTCTAATTTTATTATTTTGGTCTTTTCGTTGGATTTTCCCTTTCTTCTTTTTTTCGGGTTATCGCTCAGTTTTGAGC
AGAGGTTTACATTTTTTAAAAATTTGCTTTCCAGCCCGCCTTGATCTTCTAAGTGCGAGTTCATCGTCTGAGAAAAAAAAAAATCTCTGG
TTGGCGTTTTTGTTTCTTTTCTTTTCTTTCTTTTCTTTCCTTTTTTTTTTTTTTTAATTTTTTTCAAGGGGGAGGAGATTTTCCACAAGA
AAAGGTTGTTTTCATGTTTGGGATTCAGGAAAGCATCCAACGGAGTGGAAGCAGCATGAAGGAAGAGCCGCTGGGCAGCGGCATGAACGC
GGTGCGGACGTGGATGCAGGGCGCCGGGGTGCTGGACGCCAACACGGCGGCGCAGAGCGGGGTGGGTCTGGCCCGGGCTCACTTTGAGAA
GCAGCCGCCTTCCAATCTGCGGAAATCCAACTTCTTCCACTTCGTCCTGGCCCTCTACGACAGACAGGGCCAGCCCGTGGAGATCGAGAG
GACAGCGTTTGTGGGGTTCGTGGAGAAGGAAAAAGAAGCCAACAGCGAAAAGACCAATAACGGAATTCACTACCGGCTTCAGCTTCTCTA
CAGCAATGGGATAAGGACGGAGCAGGATTTCTACGTGCGCCTCATTGACTCCATGACAAAACAAGCCATAGTGTATGAAGGCCAAGACAA
GAACCCAGAAATGTGCCGAGTCTTGCTCACACATGAGATCATGTGCAGCCGCTGTTGTGACAAGAAAAGCTGTGGCAACCGAAATGAGAC
TCCCTCAGATCCAGTGATAATTGACAGGTTCTTCTTGAAATTTTTCCTCAAATGTAACCAAAATTGCCTAAAGAATGCGGGAAACCCACG
TGACATGCGGAGATTCCAGGTCGTGGTGTCTACGACAGTCAATGTGGATGGCCATGTCCTGGCAGTCTCTGATAACATGTTTGTCCATAA
TAATTCCAAGCATGGGCGGAGGGCTCGGAGGCTTGACCCCTCGGAAGCTACTCCCTGTATCAAAGCCATCAGCCCGAGTGAAGGATGGAC
GACGGGAGGTGCGACTGTGATCATCATAGGGGACAATTTCTTTGATGGGTTACAGGTCATATTCGGTACCATGCTGGTCTGGAGTGAGTT
GATCACTCCTCATGCCATCCGTGTGCAGACCCCTCCTCGGCACATCCCTGGTGTTGTGGAAGTCACACTGTCCTACAAATCTAAGCAGTT
CTGCAAAGGAACACCAGGCAGATTCATTTATACAGCGCTCAACGAACCCACCATCGATTATGGTTTCCAGAGGTTACAGAAGGTCATTCC
TCGGCACCCTGGTGACCCTGAGCGTTTGCCAAAGGAAGTAATACTCAAAAGGGCTGCGGATCTGGTAGAAGCACTGTATGGGATGCCACA
CAACAACCAGGAAATCATTCTGAAGAGAGCGGCCGACATTGCCGAGGCCCTGTACAGTGTTCCCCGCAACCACAACCAACTCCCGGCCCT
TGCTAACACCTCGGTCCACGCAGGGATGATGGGCGTGAATTCGTTCAGTGGACAACTGGCCGTGAATGTCTCCGAGGCATCACAAGCCAC
CAATCAGGTAGTGCCATCCAGCCCCACCATGGCCTCCTCCACAAGCCTCCCCTCCAACTGCAGCAGCTCCTCGGGCATCTTCTCCTTCTC
ACCAGCCAACATGGTCTCAGCCGTGAAACAGAAGAGTGCTTTCGCACCAGTCGTCAGACCCCAGACCTCCCCACCTCCCACCTGCACCAG
CACCAACGGGAACAGCCTGCAAGCCTTGCCCTTTAAGGTGGTGGTGATCTCAGCCATCCTGGCCCTGGTGGTGCTCACCATCATCTCCCT
TATCATCCTCATCATGCTTTGGCAGAAGAAGCCACGTTACGAGATCCGATGGAAGGTGATTGAGTCTGTGAGCTCTGACGGCCATGAGTA
CATCTACGTGGACCCCATGCAGCTGCCCTATGACTCCACGTGGGAGCTGCCGCGGGACCAGCTTGTGCTGGGACGCACCCTCGGCTCTGG
GGCCTTTGGGCAGGTGGTGGAGGCCACGGCTCATGGCCTGAGCCATTCTCAGGCCACGATGAAAGTGGCCGTCAAGATGCTTAAATCCAC
AGCCCGCAGCAGTGAGAAGCAAGCCCTTATGTCGGAGCTGAAGATCATGAGTCACCTTGGGCCCCACCTGAACGTGGTCAACCTGTTGGG
GGCCTGCACCAAAGGAGGACCCATCTATATCATCACTGAGTACTGCCGCTACGGAGACCTGGTGGACTACCTGCACCGCAACAAACACAC
CTTCCTGCAGCACCACTCCGACAAGCGCCGCCCGCCCAGCGCGGAGCTCTACAGCAATGCTCTGCCCGTTGGGCTCCCCCTGCCCAGCCA
TGTGTCCTTGACCGGGGAGAGCGACGGTGGCTACATGGACATGAGCAAGGACGAGTCGGTGGACTATGTGCCCATGCTGGACATGAAAGG
AGACGTCAAATATGCAGACATCGAGTCCTCCAACTACATGGCCCCTTACGATAACTACGTTCCCTCTGCCCCTGAGAGGACCTGCCGAGC
AACTTTGATCAACGAGTCTCCAGTGCTAAGCTACATGGACCTCGTGGGCTTCAGCTACCAGGTGGCCAATGGCATGGAGTTTCTGGCCTC
CAAGAACTGCGTCCACAGAGACCTGGCGGCTAGGAACGTGCTCATCTGTGAAGGCAAGCTGGTCAAGATCTGTGACTTTGGCCTGGCTCG
AGACATCATGCGGGACTCGAATTACATCTCCAAAGGCAGCACCTTTTTGCCTTTAAAGTGGATGGCTCCGGAGAGCATCTTCAACAGCCT
CTACACCACCCTGAGCGACGTGTGGTCCTTCGGGATCCTGCTCTGGGAGATCTTCACCTTGGGTGGCACCCCTTACCCAGAGCTGCCCAT
GAACGAGCAGTTCTACAATGCCATCAAACGGGGTTACCGCATGGCCCAGCCTGCCCATGCCTCCGACGAGATCTATGAGATCATGCAGAA
GTGCTGGGAAGAGAAGTTTGAGATTCGGCCCCCCTTCTCCCAGCTGGTGCTGCTTCTCGAGAGACTGTTGGGCGAAGGTTACAAAAAGAA
GTACCAGCAGGTGGATGAGGAGTTTCTGAGGAGTGACCACCCAGCCATCCTTCGGTCCCAGGCCCGCTTGCCTGGGTTCCATGGCCTCCG
ATCTCCCCTGGACACCAGCTCCGTCCTCTATACTGCCGTGCAGCCCAATGAGGGTGACAACGACTATATCATCCCCCTGCCTGACCCCAA
ACCCGAGGTTGCTGACGAGGGCCCACTGGAGGGTTCCCCCAGCCTAGCCAGCTCCACCCTGAATGAAGTCAACACCTCCTCAACCATCTC
CTGTGACAGCCCCCTGGAGCCCCAGGACGAACCAGAGCCAGAGCCCCAGCTTGAGCTCCAGGTGGAGCCGGAGCCAGAGCTGGAACAGTT
GCCGGATTCGGGGTGCCCTGCGCCTCGGGCGGAAGCAGAGGATAGCTTCCTGTAGGGGGCTGGCCCCTACCCTGCCCTGCCTGAAGCTCC
CCCCCTGCCAGCACCCAGCATCTCCTGGCCTGGCCTGACCGGGCTTCCTGTCAGCCAGGCTGCCCTTATCAGCTGTCCCCTTCTGGAAGC
TTTCTGCTCCTGACGTGTTGTGCCCCAAACCCTGGGGCTGGCTTAGGAGGCAAGAAAACTGCAGGGGCCGTGACCAGCCCTCTGCCTCCA
GGGAGGCCAACTGACTCTGAGCCAGGGTTCCCCCAGGGAACTCAGTTTTCCCATATGTAAAATGGGAAAGTTAGGCTTGATGACCCAGAA
TCTAGGATTCTCTCCCTGGCTGACAGGTGGGGAGACCGAATCCCTCCCTGGGAAGATTCTTGGAGTTACTGAGGTGGTAAATTAACTTTT
TTCTGTTCAGCCAGCTACCCCTCAAGGAATCATAGCTCTCTCCTCGCACTTTTATCCACCCAGGAGCTAGGGAAGAGACCCTAGCCTCCC
TGGCTGCTGGCTGAGCTAGGGCCTAGCCTTGAGCAGTGTTGCCTCATCCAGAAGAAAGCCAGTCTCCTCCCTATGATGCCAGTCCCTGCG
TTCCCTGGCCCGAGCTGGTCTGGGGCCATTAGGCAGCCTAATTAATGCTGGAGGCTGAGCCAAGTACAGGACACCCCCAGCCTGCAGCCC
TTGCCCAGGGCACTTGGAGCACACGCAGCCATAGCAAGTGCCTGTGTCCCTGTCCTTCAGGCCCATCAGTCCTGGGGCTTTTTCTTTATC
ACCCTCAGTCTTAATCCATCCACCAGAGTCTAGAAGGCCAGACGGGCCCCGCATCTGTGATGAGAATGTAAATGTGCCAGTGTGGAGTGG
CCACGTGTGTGTGCCAGTATATGGCCCTGGCTCTGCATTGGACCTGCTATGAGGCTTTGGAGGAATCCCTCACCCTCTCTGGGCCTCAGT
TTCCCCTTCAAAAAATGAATAAGTCGGACTTATTAACTCTGAGTGCCTTGCCAGCACTAACATTCTAGAGTATTCCAGGTGGTTGCACAT
TTGTCCAGATGAAGCAAGGCCATATACCCTAAACTTCCATCCTGGGGGTCAGCTGGGCTCCTGGGAGATTCCAGATCACACATCACACTC
TGGGGACTCAGGAACCATGCCCCTTCCCCAGGCCCCCAGCAAGTCTCAAGAACACAGCTGCACAGGCCTTGACTTAGAGTGACAGCCGGT
GTCCTGGAAAGCCCCCAGCAGCTGCCCCAGGGACATGGGAAGACCACGGGACCTCTTTCACTACCCACGATGACCTCCGGGGGTATCCTG
GGCAAAAGGGACAAAGAGGGCAAATGAGATCACCTCCTGCAGCCCACCACTCCAGCACCTGTGCCGAGGTCTGCGTCGAAGACAGAATGG
ACAGTGAGGACAGTTATGTCTTGTAAAAGACAAGAAGCTTCAGATGGGTACCCCAAGAAGGATGTGAGAGGTGGGCGCTTTGGAGGTTTG
CCCCTCACCCACCAGCTGCCCCATCCCTGAGGCAGCGCTCCATGGGGGTATGGTTTTGTCACTGCCCAGACCTAGCAGTGACATCTCATT
GTCCCCAGCCCAGTGGGCATTGGAGGTGCCAGGGGAGTCAGGGTTGTAGCCAAGACGCCCCCGCACGGGGAGGGTTGGGAAGGGGGTGCA
GGAAGCTCAACCCCTCTGGGCACCAACCCTGCATTGCAGGTTGGCACCTTACTTCCCTGGGATCCCCAGAGTTGGTCCAAGGAGGGAGAG
TGGGTTCTCAATACGGTACCAAAGATATAATCACCTAGGTTTACAAATATTTTTAGGACTCACGTTAACTCACATTTATACAGCAGAAAT
GCTATTTTGTATGCTGTTGAGTTTTTCTATCTGTGTACTTTTTTTTAAGGGAAAGATTTTAATATTAAACCTGGTGCTTCTCACTCACAG
A

>24821_24821_3_EBF1-PDGFRB_EBF1_chr5_158134987_ENST00000517373_PDGFRB_chr5_149506179_ENST00000261799_length(amino acids)=1135AA_BP=555
MRKKKISGWRFCFFSFLSFLSFFFFFNFFQGGGDFPQEKVVFMFGIQESIQRSGSSMKEEPLGSGMNAVRTWMQGAGVLDANTAAQSGVG
LARAHFEKQPPSNLRKSNFFHFVLALYDRQGQPVEIERTAFVGFVEKEKEANSEKTNNGIHYRLQLLYSNGIRTEQDFYVRLIDSMTKQA
IVYEGQDKNPEMCRVLLTHEIMCSRCCDKKSCGNRNETPSDPVIIDRFFLKFFLKCNQNCLKNAGNPRDMRRFQVVVSTTVNVDGHVLAV
SDNMFVHNNSKHGRRARRLDPSEATPCIKAISPSEGWTTGGATVIIIGDNFFDGLQVIFGTMLVWSELITPHAIRVQTPPRHIPGVVEVT
LSYKSKQFCKGTPGRFIYTALNEPTIDYGFQRLQKVIPRHPGDPERLPKEVILKRAADLVEALYGMPHNNQEIILKRAADIAEALYSVPR
NHNQLPALANTSVHAGMMGVNSFSGQLAVNVSEASQATNQVVPSSPTMASSTSLPSNCSSSSGIFSFSPANMVSAVKQKSAFAPVVRPQT
SPPPTCTSTNGNSLQALPFKVVVISAILALVVLTIISLIILIMLWQKKPRYEIRWKVIESVSSDGHEYIYVDPMQLPYDSTWELPRDQLV
LGRTLGSGAFGQVVEATAHGLSHSQATMKVAVKMLKSTARSSEKQALMSELKIMSHLGPHLNVVNLLGACTKGGPIYIITEYCRYGDLVD
YLHRNKHTFLQHHSDKRRPPSAELYSNALPVGLPLPSHVSLTGESDGGYMDMSKDESVDYVPMLDMKGDVKYADIESSNYMAPYDNYVPS
APERTCRATLINESPVLSYMDLVGFSYQVANGMEFLASKNCVHRDLAARNVLICEGKLVKICDFGLARDIMRDSNYISKGSTFLPLKWMA
PESIFNSLYTTLSDVWSFGILLWEIFTLGGTPYPELPMNEQFYNAIKRGYRMAQPAHASDEIYEIMQKCWEEKFEIRPPFSQLVLLLERL
LGEGYKKKYQQVDEEFLRSDHPAILRSQARLPGFHGLRSPLDTSSVLYTAVQPNEGDNDYIIPLPDPKPEVADEGPLEGSPSLASSTLNE
VNTSSTISCDSPLEPQDEPEPEPQLELQVEPEPELEQLPDSGCPAPRAEAEDSFL

--------------------------------------------------------------

Top

Fusion Gene PPI Analysis for EBF1-PDGFRB


check button Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in

ChiPPI page.


check button Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160)
HgeneHgene's interactorsTgeneTgene's interactors


check button - Retained PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenStill interaction with
HgeneEBF1chr5:158134987chr5:149506179ENST00000313708-1516197_204581.3333333333334592.0DNA
HgeneEBF1chr5:158134987chr5:149506179ENST00000313708-1516236_239581.3333333333334592.0DNA
HgeneEBF1chr5:158134987chr5:149506179ENST00000313708-151663_66581.3333333333334592.0DNA
HgeneEBF1chr5:158134987chr5:149506179ENST00000380654-1415197_204550.3333333333334561.0DNA
HgeneEBF1chr5:158134987chr5:149506179ENST00000380654-1415236_239550.3333333333334561.0DNA
HgeneEBF1chr5:158134987chr5:149506179ENST00000380654-141563_66550.3333333333334561.0DNA


check button - Lost PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


check button - Retained PPIs, but lost function due to frame-shift fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


Top

Related Drugs for EBF1-PDGFRB


check button Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.8 2021-05-08)
PartnerGeneUniProtAccDrugBank IDDrug nameDrug activityDrug typeDrug status
TgenePDGFRBP09619DB00619ImatinibAntagonistSmall moleculeApproved
TgenePDGFRBP09619DB00619ImatinibAntagonistSmall moleculeApproved
TgenePDGFRBP09619DB00619ImatinibAntagonistSmall moleculeApproved
TgenePDGFRBP09619DB06589PazopanibInhibitorSmall moleculeApproved
TgenePDGFRBP09619DB06589PazopanibInhibitorSmall moleculeApproved
TgenePDGFRBP09619DB06589PazopanibInhibitorSmall moleculeApproved
TgenePDGFRBP09619DB08896RegorafenibInhibitorSmall moleculeApproved
TgenePDGFRBP09619DB08896RegorafenibInhibitorSmall moleculeApproved
TgenePDGFRBP09619DB08896RegorafenibInhibitorSmall moleculeApproved
TgenePDGFRBP09619DB09079NintedanibInhibitorSmall moleculeApproved
TgenePDGFRBP09619DB09079NintedanibInhibitorSmall moleculeApproved
TgenePDGFRBP09619DB09079NintedanibInhibitorSmall moleculeApproved
TgenePDGFRBP09619DB10770Foreskin fibroblast (neonatal)AgonistBiotechApproved
TgenePDGFRBP09619DB10770Foreskin fibroblast (neonatal)AgonistBiotechApproved
TgenePDGFRBP09619DB10770Foreskin fibroblast (neonatal)AgonistBiotechApproved
TgenePDGFRBP09619DB14840RipretinibInhibitorSmall moleculeApproved
TgenePDGFRBP09619DB14840RipretinibInhibitorSmall moleculeApproved
TgenePDGFRBP09619DB14840RipretinibInhibitorSmall moleculeApproved
TgenePDGFRBP09619DB00102BecaplerminBiotechApproved|Investigational
TgenePDGFRBP09619DB00102BecaplerminBiotechApproved|Investigational
TgenePDGFRBP09619DB00102BecaplerminBiotechApproved|Investigational
TgenePDGFRBP09619DB00398SorafenibAntagonistSmall moleculeApproved|Investigational
TgenePDGFRBP09619DB00398SorafenibAntagonistSmall moleculeApproved|Investigational
TgenePDGFRBP09619DB00398SorafenibAntagonistSmall moleculeApproved|Investigational
TgenePDGFRBP09619DB01254DasatinibAntagonistSmall moleculeApproved|Investigational
TgenePDGFRBP09619DB01254DasatinibAntagonistSmall moleculeApproved|Investigational
TgenePDGFRBP09619DB01254DasatinibAntagonistSmall moleculeApproved|Investigational
TgenePDGFRBP09619DB01268SunitinibInhibitorSmall moleculeApproved|Investigational
TgenePDGFRBP09619DB01268SunitinibInhibitorSmall moleculeApproved|Investigational
TgenePDGFRBP09619DB01268SunitinibInhibitorSmall moleculeApproved|Investigational
TgenePDGFRBP09619DB06595MidostaurinAntagonist|InhibitorSmall moleculeApproved|Investigational
TgenePDGFRBP09619DB06595MidostaurinAntagonist|InhibitorSmall moleculeApproved|Investigational
TgenePDGFRBP09619DB06595MidostaurinAntagonist|InhibitorSmall moleculeApproved|Investigational
TgenePDGFRBP09619DB12010FostamatinibInhibitorSmall moleculeApproved|Investigational
TgenePDGFRBP09619DB12010FostamatinibInhibitorSmall moleculeApproved|Investigational
TgenePDGFRBP09619DB12010FostamatinibInhibitorSmall moleculeApproved|Investigational
TgenePDGFRBP09619DB12147ErdafitinibSubstrateSmall moleculeApproved|Investigational
TgenePDGFRBP09619DB12147ErdafitinibSubstrateSmall moleculeApproved|Investigational
TgenePDGFRBP09619DB12147ErdafitinibSubstrateSmall moleculeApproved|Investigational
TgenePDGFRBP09619DB12978PexidartinibInhibitorSmall moleculeApproved|Investigational
TgenePDGFRBP09619DB12978PexidartinibInhibitorSmall moleculeApproved|Investigational
TgenePDGFRBP09619DB12978PexidartinibInhibitorSmall moleculeApproved|Investigational
TgenePDGFRBP09619DB15822PralsetinibInhibitorSmall moleculeApproved|Investigational
TgenePDGFRBP09619DB15822PralsetinibInhibitorSmall moleculeApproved|Investigational
TgenePDGFRBP09619DB15822PralsetinibInhibitorSmall moleculeApproved|Investigational

Top

Related Diseases for EBF1-PDGFRB


check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgeneEBF1C0007621Neoplastic Cell Transformation1CTD_human
HgeneEBF1C0024301Lymphoma, Follicular1CTD_human
HgeneEBF1C0035222Respiratory Distress Syndrome, Adult1CTD_human
HgeneEBF1C0079745Lymphoma, Large-Cell, Follicular1CTD_human
HgeneEBF1C0079758Lymphoma, Mixed-Cell, Follicular1CTD_human
HgeneEBF1C0079765Lymphoma, Small Cleaved-Cell, Follicular1CTD_human
HgeneEBF1C1956130Lymphoma, Follicular, Grade 11CTD_human
HgeneEBF1C1956131Lymphoma, Follicular, Grade 31CTD_human
HgeneEBF1C1956132Lymphoma, Follicular, Grade 21CTD_human
TgeneC3554321BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 46CTD_human;GENOMICS_ENGLAND;UNIPROT
TgeneC0393590Fahr's syndrome (disorder)3GENOMICS_ENGLAND;ORPHANET
TgeneC4225270Kosaki overgrowth syndrome3CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
TgeneC4551572MYOFIBROMATOSIS, INFANTILE, 13GENOMICS_ENGLAND;UNIPROT
TgeneC0013421Dystonia2GENOMICS_ENGLAND
TgeneC0023480Leukemia, Myelomonocytic, Chronic2ORPHANET
TgeneC0023893Liver Cirrhosis, Experimental2CTD_human
TgeneC0036341Schizophrenia2PSYGENET
TgeneC0432284Infantile myofibromatosis2CTD_human;GENOMICS_ENGLAND;ORPHANET
TgeneC0004782Basal Ganglia Diseases1CTD_human
TgeneC0006663Calcinosis1CTD_human
TgeneC0015371Extrapyramidal Disorders1CTD_human
TgeneC0036337Schizoaffective Disorder1PSYGENET
TgeneC0206648Myofibromatosis1GENOMICS_ENGLAND
TgeneC0263628Tumoral calcinosis1CTD_human
TgeneC0521174Microcalcification1CTD_human
TgeneC0750951Lenticulostriate Disorders1CTD_human
TgeneC1333046Myeloproliferative Neoplasm, Unclassifiable1ORPHANET
TgeneC1866182Penttinen-Aula syndrome1CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
TgeneC3472621Myeloid neoplasm with beta-type platelet-derived growth factor receptor gene rearrangement1ORPHANET
TgeneC3714756Intellectual Disability1GENOMICS_ENGLAND